Active, not recruitingPhase 1NCT05393427

A Study of BL-B01D1 in Patients With Locally Advanced or Metastatic Urological Tumors and Other Solid Tumors

Studying Papillary renal cell carcinoma

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Sichuan Baili Pharmaceutical Co., Ltd.
Principal Investigator
Jun Guo, PHD
Peking University Cancer Hospital & Institute
Intervention
BL-B01D1(drug)
Enrollment
4 target
Eligibility
18-75 years · All sexes
Timeline
20222025

Study locations (4)

Collaborators

SystImmune Inc. · Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05393427 on ClinicalTrials.gov

Other trials for Papillary renal cell carcinoma

Additional recruiting or active studies for the same condition.

See all trials for Papillary renal cell carcinoma

← Back to all trials